Monogram Biosciences, Inc. (MGRM)
From ValueWiki
Monogram Biosciences, Inc. is a life sciences company that develops molecular diagnostic products and laboratory services that guide and target treatments. The Company's products and services are designed to enable physicians to manage infectious diseases and cancers, and enables pharmaceutical companies to develop new anti-viral therapeutics and targeted cancer therapeutics. It enables the treatment of infectious diseases like HIV/AIDS, cancer and other serious diseases.
Contents |
|
|
Company Analysis
South San Francisco, CA based Monogram Biosciences Inc., incorporated in November 1995, is a life sciences company that develops molecular diagnostic products that guide and target treatments. The Company's products are designed to provide the information that enables physicians prescribe personalized treatments for patients by matching the underlying molecular and genetic features of an individual patient's disease to the drug expected to have maximal therapeutic benefit. The company also enables pharmaceutical companies to develop new therapeutics or drugs by providing enhanced patient selection and monitoring capabilities throughout the development process. Currently the company is focused on infectious diseases HIV / AIDS) and cancer segments.
Monogram's lead products, PhenoSense and GeneSeq provide a method for measuring the impact of genetic mutations on human immunodeficiency virus (HIV) drug resistance. The Company utilizes its eTag technology, acquired through its merger with ACLARA Biosciences, Inc. (ACLARA) that was completed in December 2004. [1]
Products
Infectious Diseases
Monogram's technologies work by identifying drug resistance in viruses that cause serious infectious diseases and can also identify a patient’s tikely drug response to certain drugs. Therefore doctors can predict in advance the likelihood a drug will be effective for the patient and optimize treatment options. Making treatments more effective, and could potentially save time and lower cost of treatment. Currently the company's marketed products in this segment is focused on HIV/AIDS, but Monogram is developing assays for other infectious diseases. [2]
Monogram's Trofile ™ Co-Receptor Tropism Assay has been used for patient selection in the phase III trials of the new class of drugs called CCR5 antagonists. The first of these, Maraviroc from Monogram's partner, Pfizer ( PFE), which has been recommended for accelerated approval by an FDA panel review on 24, 2007.[3] Monogram expects that the Trofile Assay may be used for patient selection after regulatory approval of maraviroc and other CCR5 antagonists that might enter the market later. [2]
News Feed
More News...Risks
This section needs content! Click the blue edit link (to the right) to contribute.
Research Links
- Monogram Biosciences, Inc. Snapshot
- Profile at Yahoo Finance
- Profile at MoneyCentral.com
- Company Events
- Earnings Estimates
- Competitors at Yahoo Finance
- Monogram Biosciences, Inc. Leadership
- Officers and Directors at Reuters
- Salaries and Compensation at Reuters
- Insider Trades at Money Central
- Insider Trades at TheStreet.com
- Institutional Ownership at Money Central
- Monogram Biosciences, Inc. Fundamentals
- Key Statistics Yahoo Finance
- Key Ratios at Reuters
- Dividends and Returns at Morningstar
- SEC Filings at Edgar Online
- Financial Statements Quickview at Morningstar
- Historical Prices at Yahoo Finance
- Analyst Estimates
- All Press Articles
- Monogram Biosciences, Inc. Technical Analysis
- Monogram Biosciences, Inc. Message Boards
Notes
- ↑ Company Profile from Reuters
- ↑ 2.0 2.1 Form 10-k for period ending in December 31, 2006, filed on March 9, 2007. Accessed on April 13, 2007.
- ↑ Perrone, M., "FDA panel backs Pfizer HIV drug", BusinessWeek Online, April 24, 2007. Accessed on April 25, 2007.
